While these drugs (GLP-1 agonists) do have their b
Post# of 147878
Quote:
While these drugs (GLP-1 agonists) do have their benefits, among the negatives it's the gastroparesis which concerns me the most...Any idea whether it resolves with discontinuation of the drug?
In almost all cases discontinuation reverses the effects. More problematic is inflammation of the pancreas, kidneys and heart. Once inflammation starts it can go into a feedback loop that results in low level chronic inflammation after drug discontinuation. The problem with GLP-1 agonists is that they boost GLP-1 levels very high causing an imbalance, that leads to rapid weight loss but induces the side effects. That rapid weight loss is why GLP-1 agonists combined with leronlimab might reduce liver fat faster than leronlimab alone but would almost certainly increase adverse events if not serious adverse events. I think leronlimab's slower effect on reversal of liver fat via a lower increase of GLP-1, T-3/T-4 regulation (like resmetirom) and preferential expression of brown fat (good) vs. white fat (bad) would be better than added AEs and SAEs.